scout
Opinion|Videos|December 18, 2024

Overview of Frontline Luspatercept in LR-MDS

Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin levels and transfusion independence, as supported by clinical trial data.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME